Use of etanautine orphenadrine

PDMED_ETANAUTINE_ORPHENADRINE

No definition available.

Endpoint definition

FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None

321302

diagram downward connector

Check conditions None

321302

diagram downward connector
diagram bullet

Filter registries

Medicine purchases: ATC N04AB

40

diagram downward connector

Check pre-conditions, main-only, mode, ICD version None

12

diagram downward connector
diagram bullet

Check minimum number of events

Min. number of events 3

12

diagram downward connector

Include endpoints None

12

diagram downward connector
PDMED_ETANAUTINE_ORPHENADRINE

Extra metadata

First used in FinnGen datafreeze DF2

Summary Statistics

Key figures

All Female Male
?
Number of individuals
12 6 6
?
Unadjusted prevalence (%)
0.00 0.00 0.00
?
Mean age at first event (years)
50.26 48.67 51.85

?
Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: PDMED_ETANAUTINE_ORPHENADRINE – Use of etanautine orphenadrine
GWS hits:

Survival analyses between endpoints

Plot

before Use of etanautine orphenadrine
after Use of etanautine orphenadrine

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Use of etanautine orphenadrine